Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Metrics to compare | SYBX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSYBXPeersSector | |
---|---|---|---|---|
P/E Ratio | 5.1x | −0.4x | −0.4x | |
PEG Ratio | 0.05 | 0.00 | 0.00 | |
Price/Book | 1.0x | 0.4x | 2.6x | |
Price / LTM Sales | - | 10.5x | 2.9x | |
Upside (Analyst Target) | −10.2% | 53.8% | 53.5% | |
Fair Value Upside | Unlock | 16.0% | 9.5% | Unlock |